Novo-Nordisk A/S
NVOStock
$51.48−26.78%52W
Market Cap$217.46B
P/E13.84x
Div yield3.54%
Beta1.85
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-10.71%
Price vs S&P 500 (4W)14.73%
VGM Score61.15
Market Capitalization$217.46B
P/E Ratio (Annual)13.84x
Indicated Dividend Yield (Annual)3.54%
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.38
3.38
3.38
3.41
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NVONovo-Nordisk A/S | C | B | C | $51.48 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
| BMYBristol-Myers Squibb Co. | B | C | B | $60.51 |
About
Novo Nordisk is the global leader in diabetes care, commanding approximately one-third of the branded diabetes treatment market. The Danish company manufactures insulins, GLP-1 therapies, oral antidiabetics, and obesity treatments. Its smaller biopharmaceutical segment, representing less than 10% of revenue, develops protein therapies for hemophilia and related disorders.